Bayer (FRA:BAYN) Stock Rating Reaffirmed by Goldman Sachs Group

Bayer (FRA:BAYN)‘s stock had its “buy” rating reaffirmed by stock analysts at Goldman Sachs Group in a note issued to investors on Wednesday, Borsen Zeitung reports.

Several other research analysts have also recently issued reports on the company. Morgan Stanley set a €86.00 ($100.00) target price on Bayer and gave the company a “buy” rating in a research report on Monday, January 6th. Kepler Capital Markets set a €73.00 ($84.88) target price on Bayer and gave the company a “neutral” rating in a research report on Thursday, January 9th. Warburg Research set a €61.00 ($70.93) target price on Bayer and gave the company a “neutral” rating in a research report on Friday, January 17th. Sanford C. Bernstein set a €90.00 ($104.65) target price on Bayer and gave the company a “buy” rating in a research report on Tuesday. Finally, Deutsche Bank set a €70.00 ($81.40) target price on Bayer and gave the company a “neutral” rating in a research report on Thursday, October 31st. Eight equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of €81.61 ($94.90).

Shares of FRA:BAYN opened at €75.10 ($87.33) on Wednesday. Bayer has a 12-month low of €91.58 ($106.49) and a 12-month high of €123.82 ($143.98). The business’s 50 day moving average is €72.40 and its 200 day moving average is €66.63.

About Bayer

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.

Recommended Story: Price-Sales Ratio

Analyst Recommendations for Bayer (FRA:BAYN)

Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.